Progress toward development of photodynamic vaccination against infectious/malignant diseases and photodynamic mosquitocides

Kwang Poo Chang; Bala K. Kolli; Chia-Kwung Fan; Dennis K. P. Ng; Clarence T. T. Wong; Laura Manna; Raffaele Corso; Neng-Yao Shih; Robert Elliott; X. P. Jiang; Shin-Hong Shiao; Guo-Liang Fu

doi:10.1117/12.2281437

8 February 2018 Progress toward development of photodynamic vaccination against infectious/malignant diseases and photodynamic mosquitocides

Kwang Poo Chang, Bala K. Kolli, Chia-Kwung Fan, Dennis K. P. Ng, Clarence T. T. Wong, Laura Manna, Raffaele Corso, Neng-Yao Shih, Robert Elliott, X. P. Jiang, Shin-Hong Shiao, Guo-Liang Fu

Author Affiliations +

Proceedings Volume 10479, Light-Based Diagnosis and Treatment of Infectious Diseases; 1047912 (2018) https://doi.org/10.1117/12.2281437
Event: SPIE BiOS, 2018, San Francisco, California, United States

Abstract

Photodynamic therapy (PDT) uses photosensitizers (PS) that are excited with light to generate ROS in the presence of oxygen for treating various diseases. PS also has the potential use as photodynamic insecticides (PDI) and for light-inactivation of Leishmania for photodynamic vaccination (PDV). PDT-inactivated Leishmania are non-viable, but remain immunologically competent as whole-cell vaccines against leishmaniasis, and as a universal carrier for delivery of add-on vaccines against other infectious and malignant diseases. We have screened novel PS, including Zn- and Si-phthalocyanines (PC) for differential PDT activities against Leishmania, insect and mammalian cells in vitro to assess their PDI and PDV potential. Here, Zn-PC were conjugated with various functional groups. The conjugates were examined for uptake by cells as a prerequisite for their susceptibility to light-inactivation. PDT sensitivity was found to vary with cell types and PS used. PDI potential of several PS was demonstrated by their mosquito larvicidal PDT activities in vitro. PDT-inactivated Leishmania were stored frozen for PDV in several ongoing studies: [1] Open label trial with 20 sick dogs for immunotherapy of canine leishmaniasis after chemotherapy in Naples, Italy. Clinical follow-up for >3 years indicate that the PDV prolongs their survival; [2] PDV of murine models with a human lung cancer vaccine showed dramatic tumor suppression; [3] Open label trial of multiple PDV via compassionate access to 4 advanced cancer patients showed no clinically adverse effects. Two subjects remain alive. Genetic modifications of Leishmania are underway to further enhance their safety and efficacy for PDV by installation of activable mechanisms for self-destruction and spontaneous light-emission.

Citation Download Citation

Kwang Poo Chang, Bala K. Kolli, Chia-Kwung Fan, Dennis K. P. Ng, Clarence T. T. Wong, Laura Manna, Raffaele Corso, Neng-Yao Shih, Robert Elliott, X. P. Jiang, Shin-Hong Shiao, and Guo-Liang Fu "Progress toward development of photodynamic vaccination against infectious/malignant diseases and photodynamic mosquitocides", Proc. SPIE 10479, Light-Based Diagnosis and Treatment of Infectious Diseases, 1047912 (8 February 2018); https://doi.org/10.1117/12.2281437

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available